ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 815,92
-1,49%
DAX
17 932,17
-1,10%
Brent Oil
85,585
-0,36%
Bitcoin
60 221,13
-0,63%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Amarin Corp PLC (AMRN)

  7. Amarin Corp PLC (AMRN) Actualités

AMRN Amarin Corp PLC

0,9289
0,0519 (5,92%)
01 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Amarin Corp PLC AMRN NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0519 5,92% 0,9289 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,884 0,8692 0,9289 0,9209 0,877
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/4/202420:00GLOBEAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA..
22/4/202414:00GLOBEAmarin Announces Results of Annual General Meeting of..
15/4/202414:00GLOBEAmarin to Report First Quarter 2024 Financial Results and..
08/4/202414:00GLOBEAmarin Highlights Key Data Providing Mechanistic Insights..
08/4/202412:30PRNCANew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl)..
06/4/202421:30GLOBENew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent..
03/4/202414:00GLOBEAmarin Provides Update on VAZKEPA® (Icosapent Ethyl)..
25/3/202413:00GLOBEResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent..
04/3/202423:30EDGAR2Form ARS - Annual Report to Security Holders
04/3/202414:00EDGAR2Form DEF 14A - Other definitive proxy statements
29/2/202413:06EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202413:05EDGAR2Form 8-K - Current report
29/2/202413:00GLOBEAmarin Reports Fourth Quarter and Full Year 2023 Financial..
15/2/202414:00GLOBEAmarin to Report Fourth Quarter and Full Year 2023 Financial..
12/2/202414:00EDGAR2Form PRE 14A - Other preliminary proxy statements
09/2/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202413:00EDGAR2Form 8-K - Current report
24/1/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202413:30GLOBEAmarin Chairman & CEO Issue Letter to Shareholders
12/1/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202413:00EDGAR2Form 8-K - Current report
10/1/202413:00GLOBEAmarin Provides Preliminary Fourth Quarter 2023 Selected..
09/1/202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202300:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202322:20EDGAR2Form 144 - Report of proposed sale of securities
11/12/202314:00GLOBEAmarin to Present at the 42nd Annual J.P. Morgan Healthcare..
05/12/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202313:30EDGAR2Form SC 13D/A - General statement of acquisition of..
12/11/202315:00GLOBENew REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)..
03/11/202321:30EDGAR2Form 8-K - Current report
01/11/202312:05EDGAR2Form 8-K - Current report
01/11/202312:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202312:00GLOBEAmarin Reports Third Quarter 2023 Financial Results
31/10/202321:05EDGAR2Form 8-K - Current report
31/10/202317:00GLOBEAmarin Appoints Jonathan Provoost Executive Vice President,..
26/10/202314:00GLOBELatest Research Evaluating VASCEPA®/VAZKEPA® (icosapent..
19/10/202314:00GLOBE Amarin to Report Third Quarter 2023 Financial Results and..
12/9/202314:00GLOBEAmarin to Present at the 2023 Cantor Global Healthcare..
05/9/202322:15EDGAR2Form SC 13D/A - General statement of acquisition of..
17/8/202301:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
AMRN
Amarin
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés